SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2456)7/22/2005 4:55:44 PM
From: Icebrg  Respond to of 3044
 
>>Following the close of this transaction, Millennium estimates that the Company’s combined R&D and SG&A expense will be approximately 15% lower than its current level.>>

R&D + SG&A are currently running at about 600 mUSD per year.

Erik



To: Icebrg who wrote (2456)7/22/2005 5:19:58 PM
From: scaram(o)uche  Read Replies (3) | Respond to of 3044
 
Thanks.

One of the last serious posts that I made to the thread? The merger had just occurred, and I said that I was interested in the Cor oncology program.

I was loudly laughed at. Deservedly.

:-)

But, how is the FLT3 inhibitor? Anybody have a feel? Sales? Wilder?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News